Form 4: Arcutis Biotherapeutics CEO Sells Shares to Cover Tax Obligations

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 11,448 shares of common stock on May 2, 2025, at a weighted average price of $15.1919 to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On May 2, 2025, Todd Franklin Watanabe, the CEO of Arcutis Biotherapeutics, sold 11,448 shares of the company's common stock.
• The shares were sold at a weighted average price of $15.1919.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on February 13, 2024.
• Following the transaction, Watanabe directly owns 913,795 shares.
• Watanabe also has indirect ownership through several trusts and an LLC, totaling 230,140 shares.
• He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative outlook on the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial performance.

Key Dates

Keywords

Arcutis Biotherapeutics, Todd Franklin Watanabe, SEC Form 4, share sale, restricted stock units, tax obligations, beneficial ownership, ARQT